Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric juvenile psoriatic arthritis study of ustekinumab or guselkumab
ISRCTN49107623Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of ustekinumab and guselkumab in juvenile psoriatic arthritis (JPsA) (2 cohorts), sponsored by Janssen Pharmaceutical. Started Oct 2021; status: completed.
02
Drugs
ustekinumabguselkumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on ISRCTN49107623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49107623.